Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy

Background. Hematologic improvement (HI) occurs in some patients with acquired anemias and transfusional iron overload receiving iron chelation therapy (ICT) but there is little information on transfusion status after stopping chelation. Case Report. A patient with low IPSS risk RARS-T evolved to my...

Full description

Saved in:
Bibliographic Details
Main Authors: Harpreet Kochhar, Chantal S. Leger, Heather A. Leitch
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Case Reports in Hematology
Online Access:http://dx.doi.org/10.1155/2015/253294
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832550205414703104
author Harpreet Kochhar
Chantal S. Leger
Heather A. Leitch
author_facet Harpreet Kochhar
Chantal S. Leger
Heather A. Leitch
author_sort Harpreet Kochhar
collection DOAJ
description Background. Hematologic improvement (HI) occurs in some patients with acquired anemias and transfusional iron overload receiving iron chelation therapy (ICT) but there is little information on transfusion status after stopping chelation. Case Report. A patient with low IPSS risk RARS-T evolved to myelofibrosis developed a regular red blood cell (RBC) transfusion requirement. There was no response to a six-month course of study medication or to erythropoietin for three months. At 27 months of transfusion dependence, she started deferasirox and within 6 weeks became RBC transfusion independent, with the hemoglobin normalizing by 10 weeks of chelation. After 12 months of chelation, deferasirox was stopped; she remains RBC transfusion independent with a normal hemoglobin 17 months later. We report the patient’s course in detail and review the literature on HI with chelation. Discussion. There are reports of transfusion independence with ICT, but that transfusion independence may be sustained long term after stopping chelation deserves emphasis. This observation suggests that reduction of iron overload may have a lasting favorable effect on bone marrow failure in at least some patients with acquired anemias.
format Article
id doaj-art-3b64bad0d5ef4093b9a651be6ad5b016
institution Kabale University
issn 2090-6560
2090-6579
language English
publishDate 2015-01-01
publisher Wiley
record_format Article
series Case Reports in Hematology
spelling doaj-art-3b64bad0d5ef4093b9a651be6ad5b0162025-02-03T06:07:28ZengWileyCase Reports in Hematology2090-65602090-65792015-01-01201510.1155/2015/253294253294Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation TherapyHarpreet Kochhar0Chantal S. Leger1Heather A. Leitch2Department of Medicine, University of St. Eustatius, Tucker, GA 30084, USADivision of Hematology, St. Paul’s Hospital, University of British Columbia, Vancouver, BC, V6Z 2A5, CanadaDivision of Hematology, St. Paul’s Hospital, University of British Columbia, Vancouver, BC, V6Z 2A5, CanadaBackground. Hematologic improvement (HI) occurs in some patients with acquired anemias and transfusional iron overload receiving iron chelation therapy (ICT) but there is little information on transfusion status after stopping chelation. Case Report. A patient with low IPSS risk RARS-T evolved to myelofibrosis developed a regular red blood cell (RBC) transfusion requirement. There was no response to a six-month course of study medication or to erythropoietin for three months. At 27 months of transfusion dependence, she started deferasirox and within 6 weeks became RBC transfusion independent, with the hemoglobin normalizing by 10 weeks of chelation. After 12 months of chelation, deferasirox was stopped; she remains RBC transfusion independent with a normal hemoglobin 17 months later. We report the patient’s course in detail and review the literature on HI with chelation. Discussion. There are reports of transfusion independence with ICT, but that transfusion independence may be sustained long term after stopping chelation deserves emphasis. This observation suggests that reduction of iron overload may have a lasting favorable effect on bone marrow failure in at least some patients with acquired anemias.http://dx.doi.org/10.1155/2015/253294
spellingShingle Harpreet Kochhar
Chantal S. Leger
Heather A. Leitch
Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy
Case Reports in Hematology
title Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy
title_full Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy
title_fullStr Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy
title_full_unstemmed Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy
title_short Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy
title_sort durable red blood cell transfusion independence in a patient with an mds mpn overlap syndrome following discontinuation of iron chelation therapy
url http://dx.doi.org/10.1155/2015/253294
work_keys_str_mv AT harpreetkochhar durableredbloodcelltransfusionindependenceinapatientwithanmdsmpnoverlapsyndromefollowingdiscontinuationofironchelationtherapy
AT chantalsleger durableredbloodcelltransfusionindependenceinapatientwithanmdsmpnoverlapsyndromefollowingdiscontinuationofironchelationtherapy
AT heatheraleitch durableredbloodcelltransfusionindependenceinapatientwithanmdsmpnoverlapsyndromefollowingdiscontinuationofironchelationtherapy